REGN · Regeneron Pharmaceuticals, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Regeneron reported Q2 2026 revenue up 17% to $4.3 billion and non-GAAP EPS up 11% to $14.29, with Dupixent, EYLEA HD, and Libtayo setting all-time-high quarterly net sales. The company fully repaid the Sanofi Development Balance, which will step up collaboration profits starting in Q3, and raised its 2026 non-GAAP gross margin outlook.
- + Total revenue grew 17% to $4.3 billion and non-GAAP EPS grew 11% to $14.29, marking a second consecutive quarter of double-digit top- and bottom-line growth
- + Dupixent global net sales reached an all-time high of $6.0 billion, up 38%, with U.S. sales up 42% to $4.6 billion
- + EYLEA HD U.S. net sales rose 52% to an all-time high of $596 million and now represent ~60% of the U.S. retinal franchise
- + Sanofi Development Balance fully repaid; collaboration profits step up beginning Q3 2026
- + Raised 2026 non-GAAP gross margin on net product sales guidance to 84%-85% (from 83%-84%)
- − EYLEA U.S. net sales fell 45% to $412 million due to conversion to EYLEA HD, competition, and upcoming aflibercept biosimilars
- − Fianlimab Phase 3 in first-line advanced melanoma did not meet statistical significance for the primary PFS endpoint
- − GAAP net income declined 7% to $1,297 million and GAAP diluted EPS fell 5% to $12.23, weighed down by IPR&D charges and lower investment gains
- − GAAP gross margin on net product sales fell to 78% from 83% due to unabsorbed manufacturing costs from the Limerick, Ireland facility interruption
- − Q2 R&D expense rose 15% to $1,632 million and acquired IPR&D charges jumped to $127 million (vs. $10 million prior year), creating a $0.99 per-share non-GAAP drag
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REGN
this stock
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
|
ARGX
Argenx SE
|
$60.40B | +14.0% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REGN | -5.4% | -8.0% | -1.3% | -5.1% | -1.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -4.8% | -8.1% | -13.4% | -4.5% | -13.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.